Kronos Bio, Inc. (KRON)
0.8800
0.00 (0.00%)
Inactive · Last trade price on Jun 20, 2025
Kronos Bio Employees
Kronos Bio had 10 employees as of December 31, 2024. The number of employees decreased by 53 or -84.13% compared to the previous year.
Employees
10
Change (1Y)
-53
Growth (1Y)
-84.13%
Revenue / Employee
$919,200
Profits / Employee
-$6,448,500
Market Cap
53.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 10 | -53 | -84.13% | 10 | 0 |
| Dec 31, 2023 | 63 | -34 | -35.05% | 62 | 1 |
| Dec 31, 2022 | 97 | 1 | 1.04% | 97 | 0 |
| Dec 31, 2021 | 96 | 33 | 52.38% | 96 | 0 |
| Dec 31, 2020 | 63 | - | - | 63 | 0 |
KRON News
- 8 months ago - Kronos Bio Completes Sale to Concentra Biosciences - Market Watch
- 9 months ago - KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON - Business Wire
- 10 months ago - Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 11 months ago - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewsWire
- 1 year ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 1 year ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 1 year ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire